Merck Alleges Infringement Of Antibacterial Drug
In a complaint filed Monday with the U.S. District Court for the District of Delaware, Merck asked that Ranbaxy be enjoined from marketing a generic version of Primaxin in the United States.
The suit was sparked by Ranbaxy's filing of an Abbreviated New Drug Application to market generic imipenem-cilastatin, a drug that it sells in India. Imipenem-cilastatin contains the active ingredients in the drug...
To view the full article, register now.